Moving forward in the US from standard triplet regimens for the frontline treatment of transplant-ineligible, Noopur Raje, MD, from Massachusetts General Hospital, Boston, MA, discusses quadruplet protocols and the addition of antibodies to treatment regimens. Dr Raje covers the TOURMALINE-MM2 study (NCT01850524), which added ixazomib to lenalidomide-dexamethasone, and future plans to add an antibody to this regimen. She also highights two other studies which have incorporated daratumumab (MAIA; NCT02252172) and elotuzumab. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
